Posted from: Tuesday, November 25, 2014 - 03:07 PM - Present

Lemtrada Approved for Multiple Sclerosis

November 15, 2014 – Genzyme, a Sanofi company, received approval from the U.S. Food and Drug Administration (FDA) for Lemtrada™ (alemtuzumab), used in treating patients with relapsing forms of multiple sclerosis (MS) who have had an inadequate response to two or more MS therapies.  Lemtrada’s recommended dose is 12mg/day administered as a four-hour intravenous (IV) infusion on five consecutive days.  One year after the first treatment, 12mg/day on three consecutive days is recommended.

Sanofi plans on launching Lemtrada the first week of December.  Lemtrada is only available through a restricted distribution program, Lemtrada Risk Evaluation and Mitigation Strategy (REMS), which has been developed to ensure that access to Lemtrada in the U.S. is only through certified prescribers, healthcare facilities and specialty pharmacies.

 

Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by regular mail or by fax.

Actual drug patent expiration dates and availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval.  Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval.  Prices referenced are estimates based on available data and are subject to change at the time a claim is processed. Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability.

*This is provided for information purposes only.  The reference to any medication above does not imply that the medication is covered by your plan.


Last Updated Friday, September 22, 2017 - 10:04 PM.